Phase 2, Non-Interventional, Clinical Study to Assess Dystrophin Levels in Subjects With Nonsense Mutation Duchenne Muscular Dystrophy Who Have Been Treated With Ataluren for ≥9 Months
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Jan 2019
At a glance
- Drugs Ataluren (Primary)
- Indications Duchenne muscular dystrophy
- Focus Pharmacodynamics
- Sponsors PTC Therapeutics
- 10 Jan 2019 New source identified and integrated (ClinicalTrials.gov Identifier:NCT03796637)
- 04 Jan 2019 Planned number of patients changed to 6.
- 04 Jan 2019 Planned End Date changed to 5 Aug 2019.